Marie-Francoise Chesselet - Publications

University of California, Los Angeles, Los Angeles, CA 

116 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Torres ERS, Stanojlovic M, Zelikowsky M, Bonsberger J, Hean S, Mulligan C, Baldauf L, Fleming S, Masliah E, Chesselet MF, Fanselow MS, Richter F. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease. Neurobiology of Disease. 158: 105478. PMID 34390837 DOI: 10.1016/j.nbd.2021.105478  0.679
2019 Zhong H, Zhu C, Minegishi Y, Richter F, Zdunowski S, Roy RR, Vissel B, Gad P, Gerasimenko Y, Chesselet MF, Edgerton VR. Epidural Spinal Cord Stimulation Improves Motor Function in Rats With Chemically Induced Parkinsonism. Neurorehabilitation and Neural Repair. 1545968319876891. PMID 31684831 DOI: 10.1177/1545968319876891  0.607
2019 Franich NR, Hickey MA, Zhu C, Osborne GF, Ali N, Chu T, Bove NH, Lemesre V, Lerner RP, Zeitlin SO, Howland D, Neueder A, Landles C, Bates GP, Chesselet MF. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene. Journal of Neuroscience Research. PMID 31282030 DOI: 10.1002/Jnr.24493  0.339
2018 Hatami A, Zhu C, Relaño-Gines A, Elias C, Galstyan A, Jun M, Milne G, Cantor CR, Chesselet MF, Shchepinov MS. Deuterium-reinforced linoleic acid lowers lipid peroxidation and mitigates cognitive impairment in the Q140 knock in mouse model of Huntington's disease. The Febs Journal. PMID 29933522 DOI: 10.1111/Febs.14590  0.321
2018 Subramaniam SR, Magen I, Bove N, Zhu C, Lemesre V, Dutta G, Elias CJ, Lester HA, Chesselet MF. Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein. Neurobiology of Disease. PMID 29859873 DOI: 10.1016/J.Nbd.2018.05.018  0.364
2017 Reidling JC, Relaño-Ginés A, Holley SM, Ochaba J, Moore C, Fury B, Lau A, Tran AH, Yeung S, Salamati D, Zhu C, Hatami A, Cepeda C, Barry JA, Kamdjou T, ... ... Chesselet MF, et al. Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6/2 and Q140 Huntington's Disease Mice. Stem Cell Reports. PMID 29233555 DOI: 10.1016/J.Stemcr.2017.11.005  0.436
2017 Richter F, Subramaniam SR, Magen I, Lee P, Hayes J, Attar A, Zhu C, Franich NR, Bove N, De La Rosa K, Kwong J, Klärner FG, Schrader T, Chesselet MF, Bitan G. A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 28585223 DOI: 10.1007/S13311-017-0544-9  0.748
2016 Richter F, Gabby L, McDowell KA, Mulligan CK, De La Rosa K, Sioshansi PC, Mortazavi F, Cely I, Ackerson LC, Tsan L, Murphy NP, Maidment NT, Chesselet MF. Effects of decreased dopamine transporter levels on nigrostriatal neurons and paraquat/maneb toxicity in mice. Neurobiology of Aging. 51: 54-66. PMID 28038352 DOI: 10.1016/J.Neurobiolaging.2016.11.015  0.713
2016 Wrasidlo W, Tsigelny IF, Price DL, Dutta G, Rockenstein E, Schwarz TC, Ledolter K, Bonhaus D, Paulino A, Eleuteri S, Skjevik ÅA, Kouznetsova VL, Spencer B, Desplats P, Gonzalez-Ruelas T, ... ... Chesselet MF, et al. A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease. Brain : a Journal of Neurology. PMID 27679481 DOI: 10.1093/Brain/Aww238  0.366
2015 Magen I, Torres ER, Dinh D, Chung A, Masliah E, Chesselet MF. Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease. Journal of Parkinson's Disease. PMID 25588356 DOI: 10.3233/Jpd-140503  0.423
2015 Hatami A, Chesselet MF. Transgenic rodent models to study alpha-synuclein pathogenesis, with a focus on cognitive deficits. Current Topics in Behavioral Neurosciences. 22: 303-30. PMID 25218491 DOI: 10.1007/7854_2014_355  0.377
2014 Magen I, Ostritsky R, Richter F, Zhu C, Fleming SM, Lemesre V, Stewart AJ, Morimoto BH, Gozes I, Chesselet MF. Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein. Pharmacology Research & Perspectives. 2: e00065. PMID 25505609 DOI: 10.1002/Prp2.65  0.683
2014 Richter F, Fleming SM, Watson M, Lemesre V, Pellegrino L, Ranes B, Zhu C, Mortazavi F, Mulligan CK, Sioshansi PC, Hean S, De La Rosa K, Khanna R, Flanagan J, Lockhart DJ, ... ... Chesselet MF, et al. A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 840-56. PMID 25037721 DOI: 10.1007/S13311-014-0294-X  0.682
2014 Subramaniam SR, Vergnes L, Franich NR, Reue K, Chesselet MF. Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein. Neurobiology of Disease. 70: 204-13. PMID 25016198 DOI: 10.1016/J.Nbd.2014.06.017  0.47
2014 McDowell KA, Shin D, Roos KP, Chesselet MF. Sleep dysfunction and EEG alterations in mice overexpressing alpha-synuclein. Journal of Parkinson's Disease. 4: 531-9. PMID 24867919 DOI: 10.3233/Jpd-140374  0.332
2014 Richter F, Gao F, Medvedeva V, Lee P, Bove N, Fleming SM, Michaud M, Lemesre V, Patassini S, De La Rosa K, Mulligan CK, Sioshansi PC, Zhu C, Coppola G, Bordet T, ... ... Chesselet MF, et al. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons. Neurobiology of Disease. 69: 263-75. PMID 24844147 DOI: 10.1016/J.Nbd.2014.05.012  0.728
2014 Grant LM, Richter F, Miller JE, White SA, Fox CM, Zhu C, Chesselet MF, Ciucci MR. Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease. Behavioral Neuroscience. 128: 110-21. PMID 24773432 DOI: 10.1037/A0035965  0.692
2013 Fleming SM, Jordan MC, Mulligan CK, Masliah E, Holden JG, Millard RW, Chesselet MF, Roos KP. Impaired baroreflex function in mice overexpressing alpha-synuclein. Frontiers in Neurology. 4: 103. PMID 23888153 DOI: 10.3389/Fneur.2013.00103  0.395
2013 Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Progress in Neurobiology. 106: 17-32. PMID 23643800 DOI: 10.1016/J.Pneurobio.2013.04.004  0.355
2013 Watson MB, Nobuta H, Abad C, Lee SK, Bala N, Zhu C, Richter F, Chesselet MF, Waschek JA. PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in mice. Neuroscience. 240: 277-86. PMID 23500093 DOI: 10.1016/J.Neuroscience.2013.03.002  0.464
2013 Wang L, Pietra C, Liang H, Northrup SR, Chesselet M, Tache Y. Mo1992 Effect of Ghrelin Agonist, Anamorelin on Feeding, Meal Structure and Body Weight in Alpha-Synuclein Over-Expressing Mice Gastroenterology. 144. DOI: 10.1016/S0016-5085(13)62644-X  0.333
2013 Chesselet MF, Richter F, Gao F, Fleming SM, Michaud M, Zhu C, Coppola G, Bordet T, Pruss R. Mitochondria-Targeted Cholesterol Oximes Increase Dopamine-Related Gene Expression and Behavior in Mice Over-Expressing Alpha-Synuclein, a Model of Pre-Manifest Parkinson's Disease Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 128. DOI: 10.1016/B978-0-12-800044-1.00112-4  0.657
2012 Wang L, Magen I, Yuan PQ, Subramaniam SR, Richter F, Chesselet MF, Taché Y. Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 24: e425-36. PMID 22779732 DOI: 10.1111/J.1365-2982.2012.01974.X  0.698
2012 Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, Effros RB, Chesselet MF. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Experimental Neurology. 237: 318-34. PMID 22750327 DOI: 10.1016/J.Expneurol.2012.06.025  0.701
2012 Hickey MA, Zhu C, Medvedeva V, Lerner RP, Patassini S, Franich NR, Maiti P, Frautschy SA, Zeitlin S, Levine MS, Chesselet MF. Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Molecular Neurodegeneration. 7: 12. PMID 22475209 DOI: 10.1186/1750-1326-7-12  0.537
2012 Chesselet MF, Carmichael ST. Animal models of neurological disorders. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 9: 241-4. PMID 22460561 DOI: 10.1007/S13311-012-0118-9  0.355
2012 Magen I, Fleming SM, Zhu C, Garcia EC, Cardiff KM, Dinh D, De La Rosa K, Sanchez M, Torres ER, Masliah E, Jentsch JD, Chesselet MF. Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. The European Journal of Neuroscience. 35: 870-82. PMID 22356593 DOI: 10.1111/J.1460-9568.2012.08012.X  0.412
2012 Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR. A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 9: 297-314. PMID 22350713 DOI: 10.1007/S13311-012-0104-2  0.683
2012 Lerner RP, Trejo Martinez Ldel C, Zhu C, Chesselet MF, Hickey MA. Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease. Brain Research Bulletin. 87: 571-8. PMID 22326483 DOI: 10.1016/J.Brainresbull.2012.01.012  0.468
2012 McDowell K, Chesselet MF. Animal models of the non-motor features of Parkinson's disease. Neurobiology of Disease. 46: 597-606. PMID 22236386 DOI: 10.1016/J.Nbd.2011.12.040  0.375
2012 Hickey MA, Zhu C, Medvedeva V, Franich NR, Levine MS, Chesselet MF. Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease. Molecular and Cellular Neurosciences. 49: 149-57. PMID 22044764 DOI: 10.1016/J.Mcn.2011.10.007  0.51
2012 Wang L, Magen I, Richter F, Yuan P, Chesselet M, Tache Y. Tu1972 Mice Overexpressing Wild-Type Human Alpha-Synuclein Display Alterations in Colonic Myenteric Ganglia and Propulsive Colonic Motor Function Gastroenterology. 142: S-889-S-890. DOI: 10.1016/S0016-5085(12)63459-3  0.659
2011 Magen I, Chesselet MF. Mouse models of cognitive deficits due to alpha-synuclein pathology. Journal of Parkinson's Disease. 1: 217-27. PMID 23939303 DOI: 10.3233/Jpd-2011-11043  0.372
2011 Cabeza-Arvelaiz Y, Fleming SM, Richter F, Masliah E, Chesselet MF, Schiestl RH. Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons. Molecular Neurodegeneration. 6: 83. PMID 22165993 DOI: 10.1186/1750-1326-6-83  0.726
2011 Chesselet MF, Richter F. Modelling of Parkinson's disease in mice. The Lancet. Neurology. 10: 1108-18. PMID 22094131 DOI: 10.1016/S1474-4422(11)70227-7  0.645
2011 Hutson CB, Lazo CR, Mortazavi F, Giza CC, Hovda D, Chesselet MF. Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. Journal of Neurotrauma. 28: 1783-801. PMID 21644813 DOI: 10.1089/Neu.2010.1723  0.763
2011 Lam HA, Wu N, Cely I, Kelly RL, Hean S, Richter F, Magen I, Cepeda C, Ackerson LC, Walwyn W, Masliah E, Chesselet MF, Levine MS, Maidment NT. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein. Journal of Neuroscience Research. 89: 1091-102. PMID 21488084 DOI: 10.1002/Jnr.22611  0.726
2011 Fleming SM, Mulligan CK, Richter F, Mortazavi F, Lemesre V, Frias C, Zhu C, Stewart A, Gozes I, Morimoto B, Chesselet MF. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Molecular and Cellular Neurosciences. 46: 597-606. PMID 21193046 DOI: 10.1016/J.Mcn.2010.12.011  0.701
2010 Magen I, Chesselet MF. Genetic mouse models of Parkinson's disease The state of the art. Progress in Brain Research. 184: 53-87. PMID 20887870 DOI: 10.1016/S0079-6123(10)84004-X  0.384
2010 De Deurwaerdère P, Le Moine C, Chesselet MF. Selective blockade of serotonin 2C receptor enhances Fos expression specifically in the striatum and the subthalamic nucleus within the basal ganglia. Neuroscience Letters. 469: 251-5. PMID 20004702 DOI: 10.1016/J.Neulet.2009.12.006  0.312
2010 Chesselet MF, Hickey MA, Zhu C, Levine MS. Huntington's Disease: Neurodegeneration Encyclopedia of Neuroscience. 39-44. DOI: 10.1016/B978-008045046-9.00511-8  0.354
2009 Steele AD, Zhou Z, Jackson WS, Zhu C, Auluck P, Moskowitz MA, Chesselet MF, Lindquist S. Context dependent neuroprotective properties of prion protein (PrP). Prion. 3: 240-9. PMID 19901559 DOI: 10.4161/Pri.3.4.10135  0.35
2009 Richter F, Meurers BH, Zhu C, Medvedeva VP, Chesselet MF. Neurons express hemoglobin alpha- and beta-chains in rat and human brains. The Journal of Comparative Neurology. 515: 538-47. PMID 19479992 DOI: 10.1002/Cne.22062  0.685
2009 Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, Chesselet MF, Yang XW. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 1962-76. PMID 19228951 DOI: 10.1523/Jneurosci.5351-08.2009  0.501
2009 Meurers BH, Zhu C, Fernagut PO, Richter F, Hsia YC, Fleming SM, Oh M, Elashoff D, Dicarlo CD, Seaman RL, Chesselet MF. Low dose rotenone treatment causes selective transcriptional activation of cell death related pathways in dopaminergic neurons in vivo. Neurobiology of Disease. 33: 182-92. PMID 19013527 DOI: 10.1016/J.Nbd.2008.10.001  0.664
2009 Chesselet MF, Ritz B. Transcriptional regulation of α-synuclein: Insights from blood? Future Neurology. 4: 145-147. DOI: 10.2217/14796708.4.2.145  0.346
2008 Chou AP, Maidment N, Klintenberg R, Casida JE, Li S, Fitzmaurice AG, Fernagut PO, Mortazavi F, Chesselet MF, Bronstein JM. Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome. The Journal of Biological Chemistry. 283: 34696-703. PMID 18818210 DOI: 10.1074/Jbc.M802210200  0.45
2008 Hickey MA, Kosmalska A, Enayati J, Cohen R, Zeitlin S, Levine MS, Chesselet MF. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience. 157: 280-95. PMID 18805465 DOI: 10.1016/J.Neuroscience.2008.08.041  0.546
2008 Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Chesselet MF. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. The European Journal of Neuroscience. 28: 247-56. PMID 18702696 DOI: 10.1111/J.1460-9568.2008.06346.X  0.791
2008 Chesselet MF, Fleming S, Mortazavi F, Meurers B. Strengths and limitations of genetic mouse models of Parkinson's disease. Parkinsonism & Related Disorders. 14: S84-7. PMID 18585084 DOI: 10.1016/J.Parkreldis.2008.04.004  0.498
2008 Wang L, Fleming SM, Chesselet MF, Taché Y. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport. 19: 873-6. PMID 18463504 DOI: 10.1097/Wnr.0B013E3282Ffda5E  0.401
2008 Meredith GE, Sonsalla PK, Chesselet MF. Animal models of Parkinson's disease progression. Acta Neuropathologica. 115: 385-98. PMID 18273623 DOI: 10.1007/S00401-008-0350-X  0.368
2008 Reliene R, Fleming SM, Chesselet MF, Schiestl RH. Effects of antioxidants on cancer prevention and neuromotor performance in Atm deficient mice. Food and Chemical Toxicology : An International Journal Published For the British Industrial Biological Research Association. 46: 1371-7. PMID 18037553 DOI: 10.1016/J.Fct.2007.08.028  0.323
2008 Chesselet MF. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Experimental Neurology. 209: 22-7. PMID 17949715 DOI: 10.1016/J.Expneurol.2007.08.006  0.444
2007 Fernagut PO, Hutson CB, Fleming SM, Tetreaut NA, Salcedo J, Masliah E, Chesselet MF. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse (New York, N.Y.). 61: 991-1001. PMID 17879265 DOI: 10.1002/Syn.20456  0.812
2007 Chesselet MF, Plotkin JL, Wu N, Levine MS. Development of striatal fast-spiking GABAergic interneurons. Progress in Brain Research. 160: 261-72. PMID 17499119 DOI: 10.1016/S0079-6123(06)60015-0  0.756
2006 Fleming SM, Salcedo J, Hutson CB, Rockenstein E, Masliah E, Levine MS, Chesselet MF. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience. 142: 1245-53. PMID 16934409 DOI: 10.1016/J.Neuroscience.2006.07.005  0.791
2006 Riban V, Chesselet MF. Region-specific sprouting of crossed corticofugal fibers after unilateral cortical lesions in adult mice. Experimental Neurology. 197: 451-7. PMID 16321385 DOI: 10.1016/J.Expneurol.2005.10.026  0.31
2006 Chesselet M. A vaccine for Parkinson's disease? Future Neurology. 1: 21-23. DOI: 10.2217/14796708.1.1.21  0.319
2005 Fleming SM, Fernagut PO, Chesselet MF. Genetic mouse models of parkinsonism: strengths and limitations. Neurorx : the Journal of the American Society For Experimental Neurotherapeutics. 2: 495-503. PMID 16389313 DOI: 10.1602/Neurorx.2.3.495  0.395
2005 Plotkin JL, Wu N, Chesselet MF, Levine MS. Functional and molecular development of striatal fast-spiking GABAergic interneurons and their cortical inputs. The European Journal of Neuroscience. 22: 1097-108. PMID 16176351 DOI: 10.1111/J.1460-9568.2005.04303.X  0.735
2005 Hickey MA, Gallant K, Gross GG, Levine MS, Chesselet MF. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiology of Disease. 20: 1-11. PMID 16137562 DOI: 10.1016/J.Nbd.2005.01.024  0.468
2005 Mignon L, Vourc'h P, Romero-Ramos M, Osztermann P, Young HE, Lucas PA, Chesselet MF. Transplantation of multipotent cells extracted from adult skeletal muscles into the subventricular zone of adult rats. The Journal of Comparative Neurology. 491: 96-108. PMID 16127692 DOI: 10.1002/Cne.20685  0.654
2005 Gotts JE, Chesselet MF. Mechanisms of subventricular zone expansion after focal cortical ischemic injury. The Journal of Comparative Neurology. 488: 201-14. PMID 15924343 DOI: 10.1002/Cne.20609  0.7
2005 Gotts JE, Chesselet MF. Vascular changes in the subventricular zone after distal cortical lesions. Experimental Neurology. 194: 139-50. PMID 15899251 DOI: 10.1016/J.Expneurol.2005.02.001  0.67
2005 Vourc'h P, Lacar B, Mignon L, Lucas PA, Young HE, Chesselet MF. Effect of neurturin on multipotent cells isolated from the adult skeletal muscle. Biochemical and Biophysical Research Communications. 332: 215-23. PMID 15896320 DOI: 10.1016/J.Bbrc.2005.04.104  0.743
2005 Mehta A, Chesselet MF. Effect of GABA(A) receptor stimulation in the subthalamic nucleus on motor deficits induced by nigrostriatal lesions in the rat. Experimental Neurology. 193: 110-7. PMID 15817269 DOI: 10.1016/J.Expneurol.2005.01.001  0.336
2005 Gotts JE, Chesselet MF. Migration and fate of newly born cells after focal cortical ischemia in adult rats. Journal of Neuroscience Research. 80: 160-71. PMID 15751027 DOI: 10.1002/Jnr.20434  0.723
2005 Hwang DY, Fleming SM, Ardayfio P, Moran-Gates T, Kim H, Tarazi FI, Chesselet MF, Kim KS. 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 2132-7. PMID 15728853 DOI: 10.1523/Jneurosci.3718-04.2005  0.461
2005 Chesselet MF, Fernagut PO, Fleming S. Parkinson's disease models: From toxins to genes Drug Discovery Today: Disease Models. 2: 299-303. DOI: 10.1016/J.Ddmod.2005.11.008  0.387
2004 Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 9434-40. PMID 15496679 DOI: 10.1523/Jneurosci.3080-04.2004  0.541
2004 Fernagut PO, Chesselet MF. Alpha-synuclein and transgenic mouse models. Neurobiology of Disease. 17: 123-30. PMID 15474350 DOI: 10.1016/J.Nbd.2004.07.001  0.409
2004 Levine MS, Cepeda C, Hickey MA, Fleming SM, Chesselet MF. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends in Neurosciences. 27: 691-7. PMID 15474170 DOI: 10.1016/J.Tins.2004.08.008  0.471
2004 Zhu C, Vourc'h P, Fernagut PO, Fleming SM, Lacan S, Dicarlo CD, Seaman RL, Chesselet MF. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. The Journal of Comparative Neurology. 478: 418-26. PMID 15384065 DOI: 10.1002/Cne.20305  0.401
2004 Fleming SM, Zhu C, Fernagut PO, Mehta A, DiCarlo CD, Seaman RL, Chesselet MF. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Experimental Neurology. 187: 418-29. PMID 15144868 DOI: 10.1016/J.Expneurol.2004.01.023  0.364
2004 Vourc'h P, Romero-Ramos M, Chivatakarn O, Young HE, Lucas PA, El-Kalay M, Chesselet MF. Isolation and characterization of cells with neurogenic potential from adult skeletal muscle. Biochemical and Biophysical Research Communications. 317: 893-901. PMID 15081424 DOI: 10.1016/J.Bbrc.2004.03.121  0.655
2004 Young HE, Duplaa C, Romero-Ramos M, Chesselet MF, Vourc'h P, Yost MJ, Ericson K, Terracio L, Asahara T, Masuda H, Tamura-Ninomiya S, Detmer K, Bray RA, Steele TA, Hixson D, et al. Adult reserve stem cells and their potential for tissue engineering. Cell Biochemistry and Biophysics. 40: 1-80. PMID 14983110 DOI: 10.1385/Cbb:40:1:1  0.615
2003 Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF, Maidment NT, Levine MS, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. The Journal of Biological Chemistry. 278: 43628-35. PMID 12930822 DOI: 10.1074/Jbc.M308947200  0.554
2002 Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, Li H, Zeitlin S, Chesselet MF. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 8266-76. PMID 12223581 DOI: 10.1523/Jneurosci.22-18-08266.2002  0.439
2002 Romero-Ramos M, Vourc'h P, Young HE, Lucas PA, Wu Y, Chivatakarn O, Zaman R, Dunkelman N, el-Kalay MA, Chesselet MF. Neuronal differentiation of stem cells isolated from adult muscle. Journal of Neuroscience Research. 69: 894-907. PMID 12205682 DOI: 10.1002/Jnr.10374  0.682
2002 Carmichael ST, Chesselet MF. Synchronous neuronal activity is a signal for axonal sprouting after cortical lesions in the adult. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 6062-70. PMID 12122067 DOI: 10.1523/Jneurosci.22-14-06062.2002  0.326
2002 Toneff T, Mende-Mueller L, Wu Y, Hwang SR, Bundey R, Thompson LM, Chesselet MF, Hook V. Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain. Journal of Neurochemistry. 82: 84-92. PMID 12091468 DOI: 10.1046/J.1471-4159.2002.00940.X  0.331
2002 Menalled LB, Chesselet MF. Mouse models of Huntington's disease. Trends in Pharmacological Sciences. 23: 32-9. PMID 11804649 DOI: 10.1016/S0165-6147(00)01884-8  0.318
2001 Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, Levine MS. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. Journal of Neurophysiology. 86: 2667-77. PMID 11731527 DOI: 10.1152/Jn.2001.86.6.2667  0.529
2001 Mehta A, Eberle-Wang K, Chesselet MF. Increased m-CPP-induced oral dyskinesia after lesion of serotonergic neurons. Pharmacology, Biochemistry, and Behavior. 68: 347-53. PMID 11267640 DOI: 10.1016/S0091-3057(00)00476-7  0.31
2000 Mehta A, Thermos K, Chesselet MF. Increased behavioral response to dopaminergic stimulation of the subthalamic nucleus after nigrostriatal lesions. Synapse (New York, N.Y.). 37: 298-307. PMID 10891867 DOI: 10.1002/1098-2396(20000915)37:4<298::Aid-Syn7>3.0.Co;2-A  0.311
2000 De Deurwaèrdere P, Chesselet MF. Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 5170-8. PMID 10864974 DOI: 10.1523/Jneurosci.20-13-05170.2000  0.386
2000 Menalled L, Zanjani H, MacKenzie L, Koppel A, Carpenter E, Zeitlin S, Chesselet MF. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Experimental Neurology. 162: 328-42. PMID 10739639 DOI: 10.1006/Exnr.1999.7327  0.452
1999 Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES, Carpenter EM, Zanjani H, Hurst RS, Efstratiadis A, Zeitlin S, Chesselet MF. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. Journal of Neuroscience Research. 58: 515-32. PMID 10533044 DOI: 10.1002/(Sici)1097-4547(19991115)58:4<515::Aid-Jnr5>3.0.Co;2-F  0.521
1998 McLaughlin BA, Nelson D, Silver IA, Erecinska M, Chesselet MF. Methylmalonate toxicity in primary neuronal cultures. Neuroscience. 86: 279-90. PMID 9692761 DOI: 10.1016/S0306-4522(97)00594-0  0.733
1998 McLaughlin BA, Nelson D, EreciÅ„ska M, Chesselet MF. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. Journal of Neurochemistry. 70: 2406-15. PMID 9603205 DOI: 10.1046/J.1471-4159.1998.70062406.X  0.529
1997 Bordelon YM, Chesselet MF, Nelson D, Welsh F, EreciÅ„ska M. Energetic dysfunction in quinolinic acid-lesioned rat striatum. Journal of Neurochemistry. 69: 1629-39. PMID 9326292 DOI: 10.1046/J.1471-4159.1997.69041629.X  0.337
1997 Lee S, Williamson J, Lothman EW, Szele FG, Chesselet MF, Von Hagen S, Sapolsky RM, Mattson MP, Christakos S. Early induction of mRNA for calbindin-D28k and BDNF but not NT-3 in rat hippocampus after kainic acid treatment. Brain Research. Molecular Brain Research. 47: 183-94. PMID 9221916 DOI: 10.1016/S0169-328X(97)00043-0  0.59
1996 Szele FG, Chesselet MF. Cortical lesions induce an increase in cell number and PSA-NCAM expression in the subventricular zone of adult rats. The Journal of Comparative Neurology. 368: 439-54. PMID 8725350 DOI: 10.1002/(SICI)1096-9861(19960506)368:3<439::AID-CNE9>3.0.CO;2-6  0.637
1996 Ghasemzadeh MB, Sharma S, Surmeier DJ, Eberwine JH, Chesselet MF. Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study. Molecular Pharmacology. 49: 852-9. PMID 8622635  0.486
1995 Szele FG, Alexander C, Chesselet MF. Expression of molecules associated with neuronal plasticity in the striatum after aspiration and thermocoagulatory lesions of the cerebral cortex in adult rats. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 15: 4429-48. PMID 7790918 DOI: 10.1523/Jneurosci.15-06-04429.1995  0.601
1995 Delfs JM, Ellison GD, Mercugliano M, Chesselet MF. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Experimental Neurology. 133: 175-88. PMID 7544289 DOI: 10.1006/Exnr.1995.1020  0.343
1994 Szele FG, Dowling JJ, Gonzales C, Theveniau M, Rougon G, Chesselet MF. Pattern of expression of highly polysialylated neural cell adhesion molecule in the developing and adult rat striatum. Neuroscience. 60: 133-44. PMID 8052407 DOI: 10.1016/0306-4522(94)90209-7  0.619
1991 Szele FG, Artymyshyn R, Molinoff PB, Chesselet MF. Heterogeneous distribution of dopamine D2 receptor mRNA in the rat striatum: a quantitative analysis with in situ hybridization histochemistry. The Anatomical Record. 231: 548-58. PMID 1838906 DOI: 10.1002/ar.1092310416  0.598
1989 Weiss LT, Chesselet MF. Regional distribution and regulation of preprosomatostatin messenger RNA in the striatum, as revealed by in situ hybridization histochemistry. Brain Research. Molecular Brain Research. 5: 121-30. PMID 2566104 DOI: 10.1016/0169-328X(89)90003-X  0.303
1987 Romo R, Gaudry-Talarmain YM, Chéramy A, Godeheu G, Leviel V, Chesselet MF, Glowinski J, Israël M. Different effects of electrical stimulation of the mesencephalic and pontine reticular formation on the release of dopamine and acetylcholine in the cat caudate nucleus. Neuroscience Letters. 78: 57-62. PMID 3039422 DOI: 10.1016/0304-3940(87)90561-1  0.388
1986 Chesselet MF, Graybiel AM. Striatal neurons expressing somatostatin-like immunoreactivity: evidence for a peptidergic interneuronal system in the cat. Neuroscience. 17: 547-71. PMID 2422590 DOI: 10.1016/0306-4522(86)90030-8  0.511
1986 Sandell JH, Graybiel AM, Chesselet MF. A new enzyme marker for striatal compartmentalization: NADPH diaphorase activity in the caudate nucleus and putamen of the cat. The Journal of Comparative Neurology. 243: 326-34. PMID 2419368 DOI: 10.1002/cne.902430304  0.474
1984 Graybiel AM, Chesselet MF. Compartmental distribution of striatal cell bodies expressing [Met]enkephalin-like immunoreactivity. Proceedings of the National Academy of Sciences of the United States of America. 81: 7980-4. PMID 6440146 DOI: 10.1073/Pnas.81.24.7980  0.496
1983 Chéramy A, Chesselet MF, Romo R, Leviel V, Glowinski J. Effects of unilateral electrical stimulation of various thalamic nuclei on the release of dopamine from dendrites and nerve terminals of neurons of the two nigrostriatal dopaminergic pathways. Neuroscience. 8: 767-80. PMID 6866262 DOI: 10.1016/0306-4522(83)90008-8  0.457
1983 Chesselet MF, Chéramy A, Reisine TD, Lubetzki C, Desban M, Glowinski J. Local and distal effects induced by unilateral striatal application of opiates in the absence or in the presence of naloxone on the release of dopamine in both caudate nuclei and substantiae nigrae of the cat. Brain Research. 258: 229-42. PMID 6824913 DOI: 10.1016/0006-8993(83)91146-0  0.387
1983 Chesselet MF, Cheramy A, Romo R, Desban M, Glowinski J. GABA in the thalamic motor nuclei modulates dopamine release from the two dopaminergic nigrostriatal pathways in the cat. Experimental Brain Research. 51: 275-82. PMID 6617796 DOI: 10.1007/BF00237203  0.427
1983 Chesselet MF, Graybiel AM. Met-enkephalin-like and dynorphin-like immunoreactivities of the basal ganglia of the cat. Life Sciences. 33: 37-40. PMID 6141495 DOI: 10.1016/0024-3205(83)90438-1  0.424
1982 Chesselet MF, Cheramy A, Reisine T, Lubetzki C, Glowinski J. Presynaptic regulation of striatal dopamine release: in vivo and in vitro studies. Journal De Physiologie. 78: 420-5. PMID 7182487  0.403
1982 Chesselet MF, Cheramy A, Reisine TD, Lubetzki C, Glowinski J, Fournie-Zaluski MC, Roques B. Effects of various opiates including specific delta and mu agonists on dopamine release from nigrostriatal dopaminergic neurons in vitro in the rat and in vivo in the cat. Life Sciences. 31: 2291-4. PMID 6298522 DOI: 10.1016/0024-3205(82)90140-0  0.447
1982 Reisine TD, Chesselet MF, Lubetzki C, Chéramy A, Glowinski J. A role for striatal beta-adrenergic receptors in the regulation of dopamine release. Brain Research. 241: 123-30. PMID 6286040 DOI: 10.1016/0006-8993(82)91235-5  0.404
1982 Lubetzki C, Chesselet MF, Glowinski J. Modulation of dopamine release in rat striatal slices by delta opiate agonists. The Journal of Pharmacology and Experimental Therapeutics. 222: 435-40. PMID 6284911  0.366
1982 Reisine T, Chesselet MF, Glowinski J. Striatal dopamine release in vitro: a beta-adrenoceptor-regulated response not mediated through cyclic AMP. Journal of Neurochemistry. 39: 976-81. PMID 6181195 DOI: 10.1111/j.1471-4159.1982.tb11485.x  0.391
1981 Chéramy A, Leviel V, Daudet F, Guibert B, Chesselet MF, Glowinski J. Involvement of the thalamus in the reciprocal regulation of the two nigrostriatal dopaminergic pathways. Neuroscience. 6: 2657-68. PMID 7322356 DOI: 10.1016/0306-4522(81)90110-X  0.458
1981 Chesselet MF, Chéramy A, Reisine TD, Glowinski J. Morphine and delta-opiate agonists locally stimulate in vivo dopamine release in cat caudate nucleus. Nature. 291: 320-2. PMID 7231551 DOI: 10.1038/291320A0  0.385
1981 Leviel V, Chesselet MF, Glowinski J, Chéramy A. Involvement of the thalamus in the asymmetric effects of unilateral sensory stimuli on the two nigrostriatal dopaminergic pathways in the cat. Brain Research. 223: 257-72. PMID 6169401 DOI: 10.1016/0006-8993(81)91140-9  0.422
Show low-probability matches.